Author:
Lortholary A,Delozier T,Monnier A,Bourgeois H,Bougnoux P,Tubiana-Mathieu N,Riffaud J Ch,Besson D,Lotz V,Gamelin E
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Alberti AM (2000) A phase II study of docetaxel (T) and carboplatin (CBP) as second line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 19: 438 (abstract)
2. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere®): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6: 339–355
3. Bonneterre J, Roche H, Monnier A, Fargeot P, Namer M, Guastalla JP, Rios M, Serin D, Culine S, Tubiana M, Eymard JC, Assadourian S (1998) Docetaxel versus 5 fluorouracil–vinorelbine in patients with metastatic breast cancer as second line chemotherapy: a phase III study. Proceedings of the 21st Annual San Antonio Breast Cancer Symposium 223 (abstract)
4. Carmo-Pereira J, Costa FO, Henriques E (1993) Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study. Eur J Cancer 29A: 1814–1816
5. Chevallier B, Fumoleau P, Kerbrat P, Monnier A, Roche H, Goudier MJ, Herait P (1990) Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer. Am J Clin Oncol 13(Suppl 1): S40–S43
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献